A Phase 3 interventional study of SMZ1 and SMZ1 Placebo in Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy, sponsored by SANGMYUNG innovation. Recruiting at 1 site in South Korea. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by SANGMYUNG innovation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Macular Degeneration with a site in Korea, Republic of — 11 open to participants now, 13 under way, 5 of them phase 3. Macular Degeneration · Korea, Republic of.
Among the 67 studies in Macular Degeneration with a site in Korea, Republic of, this one is the 19th largest by planned enrollment of the 56 interventional ones that give a count, is one of 7 that started in 2025, is one of 22 in phase 3, reaches primary completion later than 6 of the 12 other live ones, and was the 65th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →11 of the 67 studies in Macular Degeneration with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Junyeop Lee · Sites in Korea, Republic of
Ages 50+
Yeungnam University College of Medicine · Sites in Korea, Republic of
Ages 50+
Hoffmann-La Roche · Sites in Korea, Republic of, Austria, Czechia and 10 more countries
Ages 50+
4D Molecular Therapeutics · Sites in Korea, Republic of, United States, Argentina and 14 more countries
Ages 50+
University of Wisconsin, Madison · Sites in Korea, Republic of, United States, Argentina and 4 more countries
Ages 50+ · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 22 · Phase 4 10
First in 2006; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 266 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 81 across the 56 interventional studies, 512 across the 11 observational. Of the 50 that completed or were terminated, 20 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 67 have an industry lead sponsor. The 10 most frequent:
SANGMYUNG innovation is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
SANGMYUNG innovation has 1 study filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
3 of the studies in Macular Degeneration with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT07064759Phase 34D Molecular TherapeuticsSingle Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-11 |
| NCT06924021University of Wisconsin, MadisonAge-Related Macular Degeneration Benchmark Imaging Dataset (ABID) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 67 studies in Macular Degeneration with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of SMZ1 tablets in combination with Ranibizumab compared with placebo in combination with Ranibizumab in subjects with neovascular (wet) age-related macular degeneration (nAMD) without polypoidal choroidal vasculopathy (PCV). The primary objective is to demonstrate the superiority of SMZ1 tablets over placebo with respect to improvement in best-corrected visual acuity at Month 12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A study eye satisfying all of the following criteria after screening
① Active* submacular choroidal neovascularization due to nAMD confirmed by fluorescein angiography (FAG) and optical coherence tomography (OCT)
*Fluorescence leakage confirmed via FAG and intraretinal or subretinal fluid confirmed via OCT
② Absence of active polypoidal lesions due to polypoidal choroidal vasculopathy (PCV) confirmed by indocyanine green angiography (ICGA)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SMZ1 + Ranibizumab
Drug: SMZ1
SMZ1 Placebo + Ranibizumab
Drug: SMZ1 Placebo
* Loading Phase (3 months): SMZ1 BID and Ranibizumab Monthly injection; * PRN Phase (9 months): SMZ1 BID and Ranibizumab PRN injection
* Loading Phase (3 months): SMZ1 Placebo BID and Ranibizumab monthly injection; * PRN Phase (9 months): SMZ1 Placebo BID and Ranibizumab PRN injection
Best corrected visual acuity (BCVA) at Month 12
Change in BCVA score from baseline, at Month 12 after the administration of the investigational drug using early treatment diabetic retinopathy study (ETDRS) chart
Time frame: Month 12
Monthly BCVA
Change in BCVA score from baseline, at each month after the administration of the investigational drug for 11 months (excluding Month 12) using ETDRS chart
Time frame: Monthly for 11 months
Central retinal thickness (CRT) every three months
Change in CRT from the screening visit, at Month 3, 6, and 12 after the administration of the investigational drug measured with optical coherence tomography (OCT)
Time frame: Month 3, 6, and 12
Ranibizumab retreatment
Number of Ranibizumab retreatment through Month 4 and 12, following the Ranibizumab loading phase of 3 months
Time frame: Through Month 4 and 12
Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 27 months is above that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SANGMYUNG innovation